Our current findings disclose that these genetically homogeneous leukemia cells, in terms of BCR/ABL, KIT or FLT3 mutations, are epigenetically heterogeneous and can be distinguished by overexpression of FTO and reduction of m6A methylation. This evidence concerns the gene BCR and leukemia.